tegafur has been researched along with Disease Exacerbation in 134 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to determine the maximum tolerated dose and the recommended dose of combining S-1 with gemcitabine and cisplatin for advanced biliary tract adenocarcinoma first-line therapy." | 9.22 | Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H, 2016) |
| "Gemcitabine (GEM)-based chemotherapy has been used worldwide as the first-line treatment for advanced biliary tract cancer (BTC)." | 9.17 | A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. ( Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H, 2013) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 9.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy." | 9.16 | Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. ( Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2012) |
| "To determine the efficacy and tolerance of irinotecan in combination with S-1 (IRIS) for patients whose disease progressed after treatment with an oxaliplatin-based therapy for colorectal cancer (CRC)." | 9.15 | Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. ( Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY, 2011) |
| "The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer." | 9.14 | A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K, 2009) |
| "The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer." | 9.12 | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 9.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "UFT (with leucovorin) and irinotecan both have single-agent activity in colorectal cancer, with non-cross-resistant mechanisms of action." | 9.09 | UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. ( Hill, M; Price, T, 2000) |
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 7.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)." | 7.78 | An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012) |
| " Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer." | 7.77 | A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011) |
| "4%) and renal adverse events (all grades: CS, 18." | 6.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 6.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| "At the age of 78 advanced colorectal cancer (stage IIIa) was diagnosed and laparoscopic-assisted colectomy was performed." | 5.56 | Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. ( Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Imafuku, A; Kawada, M; Mizuno, H; Ohashi, K; Sawa, N; Sekine, A; Suwabe, T; Toriu, N; Ubara, Y; Yamanouchi, M, 2020) |
| "The treatment efficacy of advanced breast cancer is still not promising." | 5.42 | Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study. ( Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y, 2015) |
| "We recently established a metastasis model in nude mice using the MKL-4 cell line, a contransfectant of the MCF-7 human breast cancer cell line with fgf-4 and lacZ in which micrometastases in several organs can be quantitatively observed." | 5.30 | Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. ( Dickson, RB; Fujioka, A; Fukumori, H; Kurebayashi, J; Kurosumi, M; Nukatsuka, M; Saito, H; Sonoo, H; Takeda, S; Unemi, N, 1997) |
| "This study aimed to determine the maximum tolerated dose and the recommended dose of combining S-1 with gemcitabine and cisplatin for advanced biliary tract adenocarcinoma first-line therapy." | 5.22 | Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H, 2016) |
| "Gemcitabine (GEM)-based chemotherapy has been used worldwide as the first-line treatment for advanced biliary tract cancer (BTC)." | 5.17 | A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. ( Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H, 2013) |
| "Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy." | 5.16 | Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. ( Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2012) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 5.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "To determine the efficacy and tolerance of irinotecan in combination with S-1 (IRIS) for patients whose disease progressed after treatment with an oxaliplatin-based therapy for colorectal cancer (CRC)." | 5.15 | Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. ( Choi, SK; Ha, CY; Ju, YT; Kang, JH; Kim, HG; Kwon, HC; Lee, GW; Lee, WS; Oh, SY, 2011) |
| "The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer." | 5.14 | A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Akaike, M; Morinaga, S; Shiozawa, M; Sugano, N; Sugimasa, Y; Tsuchida, K, 2009) |
| "The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer." | 5.12 | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G, 2007) |
| "A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan." | 5.11 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. ( Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G, 2004) |
| "UFT (with leucovorin) and irinotecan both have single-agent activity in colorectal cancer, with non-cross-resistant mechanisms of action." | 5.09 | UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. ( Hill, M; Price, T, 2000) |
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 3.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "Patients with primary, resectable, T2 or T3, N0-N1 adenocarcinoma in the lower 6 cm of the rectum were given chemoradiotherapy (60 Gy in 30 fractions to tumour, 50 Gy in 30 fractions to elective lymph node volumes, 5 Gy endorectal brachytherapy boost, and oral tegafur-uracil 300 mg/m(2)) every weekday for 6 weeks." | 3.81 | High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. ( Appelt, AL; Harling, H; Jakobsen, A; Jensen, FS; Jensen, LH; Jørgensen, JC; Lindebjerg, J; Pløen, J; Rafaelsen, SR, 2015) |
| "Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)." | 3.78 | An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012) |
| " Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer." | 3.77 | A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011) |
| "Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)." | 3.69 | Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997) |
| "Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40-60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40-60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle)." | 2.90 | TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). ( Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S, 2019) |
| "To observe the efficacy and safety of chemotherapy regimens oxaliplatin combined with capecitabine (CAPOX) or oxaliplatin combined with tegafur, gimeracil and oteracil potassium capsules (S-1)(SOX), and to investigate the value of expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) proteins in tumor tissue for predicting the efficacy of CAPOX and SOX regimens in advanced gastric cancer patients." | 2.82 | [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer]. ( Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J, 2016) |
| " Major grade 3/4 adverse events included neutropenia (28." | 2.78 | Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y, 2013) |
| "4%) and renal adverse events (all grades: CS, 18." | 2.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "Adjuvant chemotherapy trial of TS-1 for gastric cancer study demonstrated that postoperative S-1 chemotherapy for 1 year improved overall survival of locally advanced gastric cancer (LAGC) patients." | 2.78 | A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH, 2013) |
| "Advanced pancreatic cancer has a bad prognosis, with a median overall survival (OS) no longer than 4-6 months." | 2.76 | Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. ( Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E, 2011) |
| "The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%." | 2.75 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. ( Boku, N; Furuhata, T; Hyodo, I; Kato, T; Koizumi, W; Miyashita, K; Miyata, Y; Nishina, T; Okada, Y; Sawaki, A; Toh, Y; Yamaguchi, K, 2010) |
| "Patients continued treatment until disease progression, unacceptable toxicity, or withdrawal of consent." | 2.75 | An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. ( Akaza, H; Fujimoto, H; Naito, S; Tsukamoto, T; Usami, M, 2010) |
| "Patients with hormone-resistant breast cancer are assigned to either TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period) or standard chemotherapy (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)." | 2.75 | Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). ( Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T, 2010) |
| "We developed a population pharmacokinetic (PPK) model of S-1 including the cytochrome P450 (CYP) 2A6 genotype and then used this PPK model to assess the influence of the CYP2A6 genotype on PK parameters of S-1 and the relationship between toxicity and the individual maximum concentrations (Cmax) or the area under the concentration-time curve (AUC) of 5-fluorouracil (5-FU) in Japanese patients with advanced cancer." | 2.75 | Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. ( Adachi, M; Fujita, K; Hirose, T; Ishida, H; Miwa, K; Mizuno, K; Nagashima, F; Nishimura, K; Sasaki, Y; Sunakawa, Y; Tanigawara, Y; Yamashita, K, 2010) |
| "Patients with gastric cancer who have positive cytologic results for cancer cells in peritoneal washings (CY1) have poor outcomes, even in the absence of other distant metastases." | 2.74 | A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). ( Fujiwara, M; Ito, S; Kodera, Y; Kojima, H; Kojima, T; Kondo, K; Koshikawa, K; Matsui, T; Mochizuki, Y; Nakao, A; Suzuki, N; Takase, T; Tsuboi, K, 2009) |
| "Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable." | 2.73 | Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008) |
| "Biliary tract cancers are among the most aggressive tumors with a poor prognosis." | 2.73 | Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer. ( Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Lee, GW; Oh, SY, 2008) |
| "Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined." | 2.73 | A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. ( Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB, 2008) |
| "Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status." | 2.73 | A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. ( Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2007) |
| " This phase I/II study was designed to determine the maximum tolerated dose (MTD), recommended dose (RD), dose-limiting toxicity (DLT), and objective response rate of paclitaxel in combination with S-1." | 2.72 | Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. ( Aihara, R; Asao, T; Haga, N; Kamiyama, Y; Kuwano, H; Mochiki, E; Nakabayashi, T; Nakamura, J; Ohno, T; Ohsawa, H; Ojima, H; Takeuchi, K, 2006) |
| "A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC)." | 2.72 | Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. ( Ichikawa, W; Inokuchi, M; Kawano, T; Kojima, K; Nihei, Z; Sugihara, K; Yamada, H; Yamashita, T, 2006) |
| "Our aim was to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended dose of oxaliplatin combined with oral tegafur-uracil and leucovorin." | 2.71 | Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. ( Chen, JS; Huang, JS; Liau, CT; Lin, YC; Rau, KM; Wang, HM; Yang, TS, 2005) |
| ") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i." | 2.70 | Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. ( Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001) |
| "Of the 136 patients with prostate cancer enrolled in this study from April 1990 to December 1992, 69 received endocrine plus UFT therapy and the remaining 67 received endocrine-only therapy." | 2.69 | Endocrine plus uracil/tegafur therapy for prostate cancer. ( Kawada, Y; Kuriyama, M; Ohshima, S; Ono, Y; Shimizu, H; Takahashi, Y, 1999) |
| "The main toxicity was diarrhea and oral mucositis." | 2.68 | Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. ( Cheong, SK; Kim, JS; Kim, YH; Lee, JD; Park, JS; Shin, SW, 1996) |
| "We conducted a meta-analysis to compare oral S-1 and infusional 5-fluorouracil (5-FU) to determine which agent was more efficacious and less toxic in combination with PTX." | 2.50 | The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. ( Chen, X; Gao, P; Liu, H; Lu, X; Song, Y; Sun, J; Wang, Z; Xu, H; Zhang, N, 2014) |
| "Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures." | 2.42 | Palliative treatment of patients with colorectal cancer. ( Glimelius, B, 2003) |
| " Herein, we report a pretreated patient with advanced squamous cell lung cancer, who received low-dose of apatinib combined with S-1 as salvage treatment, with good long-term response." | 1.62 | Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report. ( Chen, J; Wang, J; Zou, Y, 2021) |
| "At the age of 78 advanced colorectal cancer (stage IIIa) was diagnosed and laparoscopic-assisted colectomy was performed." | 1.56 | Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report. ( Fujii, T; Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Imafuku, A; Kawada, M; Mizuno, H; Ohashi, K; Sawa, N; Sekine, A; Suwabe, T; Toriu, N; Ubara, Y; Yamanouchi, M, 2020) |
| "For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment." | 1.43 | Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin. ( Ohi, H; Ozaki, T; Seki, H; Yabusaki, H, 2016) |
| "The treatment efficacy of advanced breast cancer is still not promising." | 1.42 | Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study. ( Chen, Y; Han, C; Jiao, S; Li, J; Linghu, R; Si, W; Yang, B; Yang, J; You, J; Zhang, X; Zhu, Y, 2015) |
| "The number of lymph nodes in rectal cancer was correlated with the response of primary rectal lesions to chemoradiotherapy, and was not associated with patient survival." | 1.40 | Number of Lymph Nodes in Rectal Cancer is Correlated with Response to Preoperative Chemoradiotherapy but is not Associated with Patient Survival. ( Akahane, T; Aoyagi, Y; Fukushima, Y; Hashiguchi, Y; Hayama, T; Horiuchi, A; Ishihara, S; Matsuda, K; Nakamura, K; Nozawa, K; Shimada, R; Watanabe, T; Yamada, H, 2014) |
| "S-1 monotherapy is considered a safe and effective treatment option for recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy." | 1.40 | Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis. ( Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014) |
| "Twenty-eight patients with advanced gastric cancer underwent gastrectomy without preoperative chemotherapy." | 1.39 | Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery. ( Fujita, I; Kanazawa, Y; Kato, S; Onodera, H; Uchida, E, 2013) |
| "It may be useful for esophageal squamous cell carcinoma (ESCC); however, there are insufficient data." | 1.39 | S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. ( Akutsu, Y; Hanaoka, T; Hoshino, I; Kono, T; Matsubara, H; Narushima, K; Qin, W; Semba, Y; Tochigi, T; Uesato, M, 2013) |
| "When treating advanced and metastatic breast cancer patients with chemotherapy, it is mandatory to maintain the patients quality of life while keeping an acceptable level of antitumor activity." | 1.37 | [Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer]. ( Akizuki, M; Fujii, K; Fukutomi, T; Kobayashi, K; Kosaka, J; Mouri, Y; Nakano, S; Yorozuya, K; Yoshida, M, 2011) |
| "Thymic carcinoma is a rare intrathoracic malignant tumor, and the prognosis for patients with advanced stage of the disease is poor." | 1.36 | S-1 is an active anticancer agent for advanced thymic carcinoma. ( Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Shimokawa, T; Takagi, Y, 2010) |
| "For advanced gastric cancer (AGC), second-line chemotherapy after the failure of S-1 has not yet been established." | 1.36 | Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nishitani, H; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Takeshita, S; Yamada, Y, 2010) |
| "The outcome of stage III gastric cancer patients treated by D2 dissection followed by adjuvant chemotherapy with S-1 remains unsatisfactory." | 1.36 | A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). ( Ishiyama, A; Ito, H; Ito, S; Kinoshita, T; Kodera, Y; Mochizuki, Y; Nakao, A; Sakamoto, J; Tsuburaya, A; Yokoyama, H; Yoshikawa, T, 2010) |
| "There is no standard treatment for hepatocellular carcinoma (HCC) patients with extrahepatic metastases." | 1.35 | Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. ( Aikata, H; Azakami, T; Chayama, K; Jeong, SC; Kawakami, Y; Kawaoka, T; Mori, N; Takahashi, S; Takaki, S; Uka, K, 2008) |
| "In advanced colorectal cancer (ACC), FOLFOX4 has been accepted as a standard chemotherapeutic regimen." | 1.34 | UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. ( Brugnatelli, S; Corazza, GR; Gattoni, E; Luchena, G; Riccardi, A; Sagrada, P; Scalamogna, R; Tinelli, C; Tronconi, MC, 2007) |
| "Using S-1 against gastric cancer is common." | 1.34 | [Progression of gastric cancer observed for three and a half years under S-1 administration]. ( Baba, H; Nagahama, T; Sawada, Y; Shimoda, M; Shimoda, S; Suzuki, K, 2007) |
| "The group of 14 patients with advanced gastric cancer received combination chemotherapy with S-1 and cis-diamminedichloroplatinum (CDDP) as a neoadjuvant chemotherapy (NAC)." | 1.33 | Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer. ( Fujii, M; Kaiga, T; Kanamori, N; Kobayashi, M; Kochi, M; Takahashi, T; Takayama, T, 2006) |
| "We recently established a metastasis model in nude mice using the MKL-4 cell line, a contransfectant of the MCF-7 human breast cancer cell line with fgf-4 and lacZ in which micrometastases in several organs can be quantitatively observed." | 1.30 | Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. ( Dickson, RB; Fujioka, A; Fukumori, H; Kurebayashi, J; Kurosumi, M; Nukatsuka, M; Saito, H; Sonoo, H; Takeda, S; Unemi, N, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (3.73) | 18.2507 |
| 2000's | 44 (32.84) | 29.6817 |
| 2010's | 82 (61.19) | 24.3611 |
| 2020's | 3 (2.24) | 2.80 |
| Authors | Studies |
|---|---|
| Toriu, N | 1 |
| Sawa, N | 1 |
| Imafuku, A | 1 |
| Hasegawa, E | 1 |
| Sekine, A | 1 |
| Mizuno, H | 1 |
| Yamanouchi, M | 1 |
| Hiramatsu, R | 1 |
| Hayami, N | 1 |
| Hoshino, J | 1 |
| Kawada, M | 1 |
| Suwabe, T | 1 |
| Ohashi, K | 1 |
| Fujii, T | 1 |
| Ubara, Y | 1 |
| Chen, CY | 1 |
| Liang, SH | 1 |
| Su, YY | 1 |
| Chiang, NJ | 1 |
| Wang, HC | 1 |
| Chiu, CF | 1 |
| Chen, LT | 2 |
| Bai, LY | 1 |
| Chen, J | 2 |
| Wang, J | 1 |
| Zou, Y | 1 |
| Fukuchi, M | 1 |
| Mochiki, E | 2 |
| Ishiguro, T | 2 |
| Ogura, T | 1 |
| Sobajima, J | 1 |
| Kumagai, Y | 1 |
| Ishibashi, K | 1 |
| Ishida, H | 2 |
| Yeh, YS | 1 |
| Tsai, HL | 1 |
| Huang, CW | 1 |
| Wei, PL | 1 |
| Sung, YC | 1 |
| Tang, HC | 1 |
| Wang, JY | 1 |
| Naito, M | 1 |
| Chino, S | 1 |
| Ushiku, H | 1 |
| Nishi, Y | 1 |
| Kondo, Y | 1 |
| Kubo, H | 1 |
| Kaida, T | 1 |
| Yamashita, W | 1 |
| Takahashi, Y | 2 |
| Watanabe, M | 2 |
| Lee, BM | 1 |
| Chung, SY | 1 |
| Chang, JS | 1 |
| Lee, KJ | 1 |
| Seong, J | 2 |
| Hu, T | 1 |
| Liu, C | 1 |
| Li, Q | 1 |
| Xiong, J | 1 |
| Ma, Y | 1 |
| Wu, G | 1 |
| Zhao, Y | 2 |
| Matsuda, C | 1 |
| Ishiguro, M | 1 |
| Teramukai, S | 1 |
| Kajiwara, Y | 1 |
| Fujii, S | 2 |
| Kinugasa, Y | 1 |
| Nakamoto, Y | 1 |
| Kotake, M | 1 |
| Sakamoto, Y | 2 |
| Kurachi, K | 1 |
| Maeda, A | 1 |
| Komori, K | 1 |
| Tomita, N | 1 |
| Shimada, Y | 4 |
| Takahashi, K | 1 |
| Kotake, K | 1 |
| Mochizuki, H | 1 |
| Nakagawa, Y | 1 |
| Sugihara, K | 2 |
| Venkatesan, P | 1 |
| Feng, Q | 1 |
| Zhao, JR | 1 |
| Zhang, AX | 1 |
| Li, SL | 1 |
| Ioka, T | 3 |
| Ueno, M | 2 |
| Ueno, H | 5 |
| Park, JO | 1 |
| Chang, HM | 1 |
| Sasahira, N | 4 |
| Kanai, M | 2 |
| Chung, IJ | 1 |
| Ikeda, M | 6 |
| Nakamori, S | 4 |
| Mizuno, N | 2 |
| Omuro, Y | 2 |
| Yamaguchi, T | 3 |
| Hara, H | 2 |
| Sugimori, K | 2 |
| Furuse, J | 5 |
| Maguchi, H | 3 |
| Furukawa, M | 2 |
| Fukuzawa, K | 2 |
| Kim, JS | 2 |
| Yukisawa, S | 1 |
| Takeuchi, M | 2 |
| Okusaka, T | 7 |
| Boku, N | 5 |
| Hyodo, I | 4 |
| Imataka, H | 1 |
| Sato, A | 3 |
| Hamada, K | 1 |
| Takeda, N | 1 |
| Nemoto, H | 1 |
| Suzuki, E | 1 |
| Ohkawa, S | 2 |
| Nagakawa, T | 1 |
| Yanagimoto, H | 1 |
| Sato, T | 1 |
| Akutsu, Y | 1 |
| Kono, T | 1 |
| Uesato, M | 1 |
| Hoshino, I | 1 |
| Narushima, K | 1 |
| Hanaoka, T | 1 |
| Tochigi, T | 1 |
| Semba, Y | 1 |
| Qin, W | 1 |
| Matsubara, H | 1 |
| Iwase, H | 1 |
| Shimada, M | 1 |
| Tsuzuki, T | 1 |
| Hirashima, N | 1 |
| Okeya, M | 1 |
| Hibino, Y | 1 |
| Ryuge, N | 1 |
| Yokoi, M | 1 |
| Kida, Y | 1 |
| Kuno, T | 1 |
| Tanaka, Y | 1 |
| Kato, B | 1 |
| Esaki, M | 1 |
| Urata, N | 1 |
| Kato, E | 1 |
| Ajani, JA | 1 |
| Buyse, M | 1 |
| Lichinitser, M | 1 |
| Gorbunova, V | 1 |
| Bodoky, G | 1 |
| Douillard, JY | 1 |
| Cascinu, S | 1 |
| Heinemann, V | 1 |
| Zaucha, R | 1 |
| Carrato, A | 1 |
| Ferry, D | 1 |
| Moiseyenko, V | 1 |
| Park, I | 1 |
| Ryu, MH | 1 |
| Choi, YH | 1 |
| Kang, HJ | 1 |
| Yook, JH | 1 |
| Park, YS | 1 |
| Kim, HJ | 2 |
| Jung, HY | 1 |
| Lee, GH | 1 |
| Kim, KC | 1 |
| Kim, BS | 1 |
| Kang, YK | 1 |
| Wang, M | 1 |
| Shi, SB | 1 |
| Qi, JL | 1 |
| Tang, XY | 1 |
| Tian, J | 1 |
| Terazawa, T | 1 |
| Iwasa, S | 1 |
| Takashima, A | 2 |
| Nishitani, H | 2 |
| Honma, Y | 1 |
| Kato, K | 3 |
| Hamaguchi, T | 3 |
| Yamada, Y | 4 |
| Kanazawa, Y | 1 |
| Kato, S | 1 |
| Fujita, I | 1 |
| Onodera, H | 1 |
| Uchida, E | 1 |
| Tan, C | 1 |
| Peng, L | 1 |
| Zeng, X | 1 |
| Li, J | 2 |
| Wan, X | 1 |
| Chen, G | 1 |
| Yi, L | 1 |
| Luo, X | 1 |
| Zhao, Z | 1 |
| He, MM | 1 |
| Wu, WJ | 1 |
| Wang, F | 1 |
| Wang, ZQ | 1 |
| Zhang, DS | 1 |
| Luo, HY | 1 |
| Qiu, MZ | 1 |
| Wang, FH | 1 |
| Ren, C | 1 |
| Zeng, ZL | 1 |
| Xu, RH | 1 |
| Hayakawa, N | 1 |
| Matsumoto, K | 1 |
| Sakamoto, H | 1 |
| Ezaki, T | 1 |
| Maeda, T | 2 |
| Ninomiya, A | 1 |
| Nakamura, S | 1 |
| Liu, GF | 1 |
| Tang, D | 1 |
| Li, P | 1 |
| Wang, S | 1 |
| Xu, YX | 1 |
| Long, AH | 1 |
| Zhou, NL | 1 |
| Zhang, LL | 1 |
| Xiang, XX | 1 |
| Peng, PJ | 1 |
| Cheng, H | 1 |
| Ou, XQ | 1 |
| Zeng, LJ | 1 |
| Wu, X | 1 |
| Liu, YM | 1 |
| Lin, Z | 1 |
| Tang, YN | 1 |
| Wang, SY | 1 |
| Zhang, HY | 1 |
| Chen, ZB | 1 |
| Aoe, K | 2 |
| Takigawa, N | 2 |
| Hotta, K | 2 |
| Kishino, D | 2 |
| Nogami, N | 2 |
| Tabata, M | 2 |
| Harita, S | 2 |
| Okada, T | 2 |
| Kubo, T | 1 |
| Hosokawa, S | 2 |
| Fujiwara, K | 1 |
| Gemba, K | 2 |
| Yasugi, M | 1 |
| Kozuki, T | 2 |
| Kato, Y | 2 |
| Katsui, K | 1 |
| Kanazawa, S | 2 |
| Ueoka, H | 2 |
| Tanimoto, M | 2 |
| Kiura, K | 2 |
| Yang, J | 2 |
| Zhou, Y | 1 |
| Min, K | 1 |
| Yao, Q | 1 |
| Xu, CN | 1 |
| Ke, QH | 1 |
| Zhou, SQ | 1 |
| Yang, JY | 1 |
| Du, W | 1 |
| Liang, G | 1 |
| Lei, Y | 1 |
| Luo, F | 1 |
| Liu, H | 1 |
| Chen, X | 1 |
| Sun, J | 1 |
| Gao, P | 1 |
| Song, Y | 1 |
| Zhang, N | 1 |
| Lu, X | 1 |
| Xu, H | 1 |
| Wang, Z | 1 |
| Segawa, Y | 1 |
| Oze, I | 1 |
| Kuyama, S | 1 |
| Inoue, K | 1 |
| Shibayama, T | 1 |
| Takemoto, M | 1 |
| Sasaki, T | 4 |
| Isayama, H | 5 |
| Nakai, Y | 4 |
| Ito, Y | 3 |
| Yasuda, I | 1 |
| Toda, N | 2 |
| Yagioka, H | 3 |
| Matsubara, S | 3 |
| Hanada, K | 1 |
| Kamada, H | 1 |
| Hasebe, O | 1 |
| Mukai, T | 1 |
| Okabe, Y | 1 |
| Maetani, I | 1 |
| Koike, K | 3 |
| Yasumatsu, R | 1 |
| Nakashima, T | 1 |
| Yamauchi, M | 1 |
| Toh, S | 1 |
| Komune, S | 1 |
| Nishikawa, K | 2 |
| Fujitani, K | 1 |
| Inagaki, H | 1 |
| Akamaru, Y | 1 |
| Tokunaga, S | 1 |
| Takagi, M | 1 |
| Tamura, S | 1 |
| Sugimoto, N | 2 |
| Shigematsu, T | 1 |
| Yoshikawa, T | 2 |
| Nakamura, M | 1 |
| Morita, S | 4 |
| Miyashita, Y | 1 |
| Tsuburaya, A | 3 |
| Sakamoto, J | 5 |
| Tsujinaka, T | 1 |
| Appelt, AL | 1 |
| Pløen, J | 1 |
| Harling, H | 1 |
| Jensen, FS | 1 |
| Jensen, LH | 1 |
| Jørgensen, JC | 1 |
| Lindebjerg, J | 1 |
| Rafaelsen, SR | 1 |
| Jakobsen, A | 1 |
| Ishihara, S | 2 |
| Fukushima, Y | 1 |
| Akahane, T | 1 |
| Horiuchi, A | 1 |
| Shimada, R | 1 |
| Nakamura, K | 2 |
| Aoyagi, Y | 1 |
| Hayama, T | 1 |
| Yamada, H | 3 |
| Nozawa, K | 1 |
| Matsuda, K | 1 |
| Hashiguchi, Y | 1 |
| Watanabe, T | 4 |
| Lu, M | 1 |
| Wang, Y | 1 |
| Liu, W | 1 |
| Bai, C | 1 |
| Xu, J | 1 |
| Shen, L | 1 |
| Umemura, A | 1 |
| Nitta, H | 1 |
| Sasaki, A | 1 |
| Takahara, T | 1 |
| Hasegawa, Y | 1 |
| Wakabayashi, G | 1 |
| Seki, H | 2 |
| Ohi, H | 1 |
| Ozaki, T | 1 |
| Yabusaki, H | 1 |
| Kaira, K | 1 |
| Naruse, I | 1 |
| Imai, H | 1 |
| Sunaga, N | 1 |
| Hisada, T | 1 |
| Motegi, M | 1 |
| Asao, T | 2 |
| Yamada, M | 1 |
| Mouri, A | 1 |
| Hamamoto, Y | 2 |
| Kameyama, N | 1 |
| Ibe, T | 1 |
| Takeoka, S | 1 |
| Honma, C | 1 |
| Fukusumi, M | 1 |
| Kamimura, M | 1 |
| You, J | 1 |
| Si, W | 1 |
| Zhu, Y | 1 |
| Chen, Y | 1 |
| Yang, B | 1 |
| Han, C | 1 |
| Linghu, R | 1 |
| Zhang, X | 1 |
| Jiao, S | 1 |
| Takashima, T | 2 |
| Mukai, H | 2 |
| Hara, F | 1 |
| Matsubara, N | 1 |
| Saito, T | 1 |
| Takano, T | 1 |
| Park, Y | 1 |
| Toyama, T | 1 |
| Hozumi, Y | 2 |
| Tsurutani, J | 1 |
| Imoto, S | 1 |
| Sagara, Y | 1 |
| Nishimura, R | 1 |
| Shimozuma, K | 1 |
| Ohashi, Y | 3 |
| Fukutomi, A | 1 |
| Iguchi, H | 2 |
| Shimada, K | 2 |
| Baba, H | 2 |
| Komatsu, Y | 2 |
| Shoji, H | 1 |
| Morizane, C | 3 |
| Kondo, S | 1 |
| Takahashi, H | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Mitsunaga, S | 1 |
| Wan, Y | 1 |
| Hui, H | 1 |
| Wang, X | 1 |
| Wu, J | 1 |
| Sun, S | 1 |
| Okuma, Y | 2 |
| Hosomi, Y | 2 |
| Miyamoto, S | 1 |
| Shibuya, M | 2 |
| Okamura, T | 2 |
| Hishima, T | 1 |
| Shigeta, K | 1 |
| Hasegawa, H | 1 |
| Okabayashi, K | 1 |
| Tsuruta, M | 1 |
| Ishii, Y | 1 |
| Endo, T | 1 |
| Ochiai, H | 1 |
| Kondo, T | 1 |
| Kitagawa, Y | 1 |
| Nozawa, H | 1 |
| Kawai, K | 1 |
| Murono, K | 1 |
| Yasuda, K | 1 |
| Otani, K | 1 |
| Nishikawa, T | 1 |
| Tanaka, T | 1 |
| Kiyomatsu, T | 1 |
| Hata, K | 1 |
| Ishido, K | 1 |
| Gotoh, M | 2 |
| Bando, H | 1 |
| Nishina, T | 3 |
| Amagai, K | 1 |
| Chin, K | 2 |
| Niwa, Y | 1 |
| Tsuji, A | 1 |
| Imamura, H | 2 |
| Tsuda, M | 1 |
| Yasui, H | 2 |
| Fujii, H | 2 |
| Yamaguchi, K | 2 |
| Hironaka, S | 1 |
| Miwa, H | 1 |
| Hamada, C | 2 |
| Wang, HY | 1 |
| Yao, ZH | 1 |
| Tang, H | 1 |
| Jin, SL | 1 |
| Zhou, WP | 1 |
| Yao, SN | 1 |
| Yang, SJ | 1 |
| Liu, YY | 1 |
| Luo, SX | 1 |
| Koh, M | 1 |
| Kishi, K | 1 |
| Tsukada, R | 1 |
| Tanemura, M | 1 |
| Tei, M | 1 |
| Masuzawa, T | 1 |
| Suzuki, Y | 1 |
| Furukawa, K | 1 |
| Ikehara, M | 1 |
| Akamatsu, H | 1 |
| Miyakawa, H | 1 |
| Satoh, T | 1 |
| Ito, T | 1 |
| Matsumoto, S | 2 |
| Egawa, S | 2 |
| Hatori, T | 1 |
| Mizumoto, K | 1 |
| Yamao, K | 1 |
| Funakoshi, A | 1 |
| Chen, JS | 3 |
| Cheng, AL | 2 |
| Tanaka, M | 1 |
| Kakiuchi, S | 1 |
| Hanibuchi, M | 1 |
| Tezuka, T | 1 |
| Saijo, A | 1 |
| Otsuka, K | 1 |
| Sakaguchi, S | 1 |
| Toyoda, Y | 1 |
| Goto, H | 1 |
| Kawano, H | 1 |
| Azuma, M | 1 |
| Ogushi, F | 1 |
| Nishioka, Y | 1 |
| Park, SH | 1 |
| Kim, YS | 1 |
| Hong, J | 1 |
| Park, J | 1 |
| Nam, E | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Rau, KM | 2 |
| Chen, YY | 1 |
| Huang, JS | 2 |
| Yang, TS | 2 |
| Lin, YC | 2 |
| Liau, CT | 2 |
| Lee, KD | 1 |
| Su, YC | 1 |
| Kao, RH | 1 |
| Uka, K | 1 |
| Aikata, H | 1 |
| Mori, N | 1 |
| Takaki, S | 1 |
| Kawakami, Y | 1 |
| Azakami, T | 1 |
| Kawaoka, T | 1 |
| Jeong, SC | 1 |
| Takahashi, S | 2 |
| Chayama, K | 1 |
| Kim, HM | 1 |
| Bang, S | 1 |
| Park, JY | 1 |
| Song, SY | 1 |
| Chung, JB | 1 |
| Park, SW | 1 |
| Oh, SY | 3 |
| Lee, GW | 2 |
| Kim, HG | 3 |
| Kim, TH | 1 |
| Kang, JH | 2 |
| Shiozawa, M | 1 |
| Sugano, N | 1 |
| Tsuchida, K | 1 |
| Morinaga, S | 1 |
| Akaike, M | 1 |
| Sugimasa, Y | 1 |
| Ueshima, K | 1 |
| Kudo, M | 1 |
| Nagai, T | 1 |
| Tatsumi, C | 1 |
| Ueda, T | 1 |
| Hatanaka, K | 1 |
| Kitai, S | 1 |
| Ishikawa, E | 1 |
| Inoue, T | 1 |
| Hagiwara, S | 1 |
| Minami, Y | 1 |
| Chung, H | 1 |
| Uyama, T | 1 |
| Kanazawa, A | 1 |
| Amatsu, H | 1 |
| Yamane, H | 1 |
| Kusuki, M | 1 |
| Nakamura, A | 2 |
| Park, IJ | 1 |
| Choi, GS | 1 |
| Lim, KH | 1 |
| Kang, BM | 1 |
| Jun, SH | 1 |
| Kodera, Y | 2 |
| Ito, S | 2 |
| Mochizuki, Y | 2 |
| Kondo, K | 1 |
| Koshikawa, K | 1 |
| Suzuki, N | 1 |
| Kojima, H | 1 |
| Kojima, T | 2 |
| Matsui, T | 1 |
| Takase, T | 1 |
| Tsuboi, K | 1 |
| Fujiwara, M | 1 |
| Nakao, A | 2 |
| Tokugawa, T | 1 |
| Kobayashi, A | 1 |
| Okubo, K | 1 |
| Matsuyama, T | 1 |
| Imai, S | 1 |
| Koyama, H | 1 |
| Inagaki, M | 1 |
| Onuki, T | 1 |
| Iguchi, K | 1 |
| Ogata, T | 1 |
| Hayashi, Y | 1 |
| Saito, K | 1 |
| Wakai, Y | 1 |
| Takabe, K | 1 |
| Shinohara, Y | 1 |
| Suzuki, K | 2 |
| Ohtani, T | 1 |
| Horikoshi, K | 1 |
| Yashima, Y | 2 |
| Kogure, H | 3 |
| Arizumi, T | 1 |
| Togawa, O | 2 |
| Hirano, K | 3 |
| Tsujino, T | 2 |
| Tada, M | 3 |
| Kawabe, T | 1 |
| Omata, M | 2 |
| Takiguchi, Y | 1 |
| Tada, Y | 1 |
| Gemma, A | 1 |
| Kudoh, S | 1 |
| Hino, M | 1 |
| Yoshimori, K | 1 |
| Yoshimura, A | 1 |
| Nagao, K | 1 |
| Niitani, H | 1 |
| Koizumi, W | 1 |
| Miyata, Y | 1 |
| Sawaki, A | 1 |
| Kato, T | 1 |
| Toh, Y | 1 |
| Furuhata, T | 1 |
| Miyashita, K | 1 |
| Okada, Y | 1 |
| Yokoyama, T | 1 |
| Tokuhara, H | 1 |
| Egawa, T | 1 |
| Hashimoto, O | 1 |
| Koyanagi, K | 1 |
| Bessho, T | 1 |
| Takakuwa, O | 1 |
| Oguri, T | 1 |
| Sato, S | 1 |
| Nakao, M | 1 |
| Ohta, C | 1 |
| Iwashima, Y | 1 |
| Miyazaki, M | 1 |
| Maeno, K | 1 |
| Kutsuna, T | 1 |
| Ueda, R | 1 |
| Pérez-Regadera, J | 1 |
| Sánchez-Muñoz, A | 1 |
| De-la-Cruz, J | 1 |
| Ballestín, C | 1 |
| Lora, D | 1 |
| García-Martín, R | 1 |
| Alonso-Carrión, L | 1 |
| Mendiola, C | 1 |
| Lanzós, E | 1 |
| Naito, S | 1 |
| Tsukamoto, T | 1 |
| Usami, M | 1 |
| Fujimoto, H | 1 |
| Akaza, H | 1 |
| Ju, YT | 1 |
| Choi, SK | 1 |
| Ha, CY | 1 |
| Lee, WS | 1 |
| Kwon, HC | 1 |
| Kim, JY | 1 |
| Do, YR | 1 |
| Park, KU | 1 |
| Kim, JG | 1 |
| Chae, YS | 1 |
| Kim, MK | 1 |
| Lee, KH | 2 |
| Ryoo, HM | 1 |
| Bae, SH | 1 |
| Baek, JH | 1 |
| Song, HS | 1 |
| Murakami, S | 1 |
| Masuda, N | 2 |
| Mitsuyama, S | 1 |
| Ohmura, T | 1 |
| Yajima, T | 1 |
| Hirose, T | 1 |
| Fujita, K | 1 |
| Nishimura, K | 1 |
| Yamashita, K | 1 |
| Sunakawa, Y | 1 |
| Mizuno, K | 1 |
| Miwa, K | 1 |
| Nagashima, F | 1 |
| Tanigawara, Y | 1 |
| Adachi, M | 1 |
| Sasaki, Y | 1 |
| Hashiguchi, K | 1 |
| Kitajima, Y | 1 |
| Kai, K | 1 |
| Hiraki, M | 1 |
| Nakamura, J | 2 |
| Tokunaga, O | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 1 |
| Sudo, K | 1 |
| Ishihara, T | 1 |
| Hara, T | 1 |
| Denda, T | 1 |
| Tawada, K | 1 |
| Imagumbai, T | 1 |
| Araki, H | 1 |
| Sakai, M | 1 |
| Hatano, K | 1 |
| Kawakami, H | 1 |
| Uno, T | 1 |
| Ito, H | 2 |
| Yokosuka, O | 1 |
| Ueda, Y | 1 |
| Yamagishi, H | 1 |
| Ichikawa, D | 1 |
| Okamoto, K | 1 |
| Otsuji, E | 1 |
| Morii, J | 1 |
| Koizumi, K | 1 |
| Kakihara, N | 1 |
| Shimotsuma, M | 1 |
| Yamashita, T | 2 |
| Taniguchi, F | 1 |
| Aragane, H | 1 |
| Nishi, H | 1 |
| Itokawa, Y | 1 |
| Takahari, D | 2 |
| Takeshita, S | 1 |
| Okita, N | 1 |
| Hirashima, Y | 1 |
| Shirao, K | 2 |
| Ishiyama, A | 1 |
| Kinoshita, T | 2 |
| Yokoyama, H | 1 |
| Mizuno, S | 2 |
| Yamamoto, K | 2 |
| Kawakubo, K | 2 |
| Shimokawa, T | 1 |
| Takagi, Y | 1 |
| Iguchi, M | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 1 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Maruyama, T | 1 |
| Kohno, N | 1 |
| Shitara, K | 1 |
| Yuki, S | 1 |
| Yoshida, M | 2 |
| Utsunomiya, S | 1 |
| Yokota, T | 1 |
| Sato, Y | 2 |
| Inaba, Y | 1 |
| Tajika, M | 1 |
| Kawai, H | 1 |
| Yamaura, H | 1 |
| Kato, M | 1 |
| Yamazaki, K | 1 |
| Muro, K | 1 |
| Pericay Pijaume, C | 1 |
| Escudero Emperador, P | 1 |
| Bastús Piulats, R | 1 |
| Campos Cervera, JM | 1 |
| Esquerdo Galiana, G | 1 |
| Gallén Castillo, M | 1 |
| Alfaro Gamero, J | 1 |
| Dotor Navarro, E | 1 |
| Pisa Gatell, A | 1 |
| Guasch Jordán, I | 1 |
| Saigí Grau, E | 1 |
| Narahara, H | 1 |
| Iishi, H | 1 |
| Imamoto, H | 1 |
| Esaki, T | 1 |
| Furukawa, H | 1 |
| Sakata, Y | 1 |
| Shiroyama, T | 1 |
| Komuta, K | 1 |
| Imamura, F | 1 |
| Hirashima, T | 1 |
| Kijima, T | 1 |
| Tachibana, I | 1 |
| Kawase, I | 1 |
| Zaima, C | 1 |
| Ishikawa, S | 1 |
| Kawaguchi, Y | 1 |
| Masui, T | 1 |
| Mori, Y | 1 |
| Nishimura, T | 1 |
| Yanagihara, K | 1 |
| Chiba, T | 1 |
| Mimori, T | 1 |
| Takagawa, R | 1 |
| Kunisaki, C | 1 |
| Makino, H | 1 |
| Nagano, Y | 1 |
| Kimura, J | 1 |
| Kosaka, T | 1 |
| Ono, HA | 1 |
| Akiyama, H | 1 |
| Endo, I | 1 |
| Kawaguchi, K | 1 |
| Sato, K | 1 |
| Horie, A | 1 |
| Nomura, T | 1 |
| Iketani, S | 1 |
| Kanai, I | 1 |
| Suzuki, S | 1 |
| Nakatani, Y | 1 |
| Hamada, Y | 1 |
| Fujii, K | 1 |
| Kosaka, J | 1 |
| Mouri, Y | 1 |
| Yorozuya, K | 1 |
| Nakano, S | 2 |
| Akizuki, M | 1 |
| Fukutomi, T | 1 |
| Kobayashi, K | 2 |
| Wada, M | 1 |
| Yamamoto, M | 1 |
| Ryuge, S | 1 |
| Nagashima, Y | 1 |
| Hayashi, N | 1 |
| Maki, S | 1 |
| Otani, S | 1 |
| Katono, K | 1 |
| Takakura, A | 1 |
| Yanaihara, T | 1 |
| Igawa, S | 1 |
| Yokoba, M | 1 |
| Mitsufuji, H | 1 |
| Kubota, M | 1 |
| Katagiri, M | 1 |
| Kim, GM | 1 |
| Jeung, HC | 2 |
| Rha, SY | 2 |
| Kim, HS | 1 |
| Jung, I | 1 |
| Nam, BH | 1 |
| Chung, HC | 2 |
| Kawahara, H | 1 |
| Watanabe, K | 1 |
| Toyama, Y | 1 |
| Yanagisawa, S | 1 |
| Kobayashi, S | 1 |
| Yanaga, K | 1 |
| Katayose, Y | 1 |
| Ohtsuka, H | 1 |
| Kitamura, Y | 1 |
| Masuda, K | 1 |
| Nakagawa, K | 1 |
| Yoshida, H | 1 |
| Onogawa, T | 1 |
| Motoi, F | 1 |
| Naitoh, T | 1 |
| Rikiyama, T | 1 |
| Unno, M | 1 |
| Matsuno, Y | 1 |
| Kochi, M | 2 |
| Fujii, M | 2 |
| Kanamori, N | 2 |
| Kaiga, T | 2 |
| Mihara, Y | 1 |
| Funada, T | 1 |
| Miyazaki, T | 1 |
| Takayama, T | 2 |
| Takahara, N | 1 |
| Satoh, Y | 1 |
| Takai, D | 1 |
| Hamada, T | 1 |
| Uchino, R | 1 |
| Miyabayashi, K | 1 |
| Mohri, D | 1 |
| Yamamoto, N | 1 |
| Ijichi, H | 1 |
| Yatomi, Y | 1 |
| Lee, T | 1 |
| Tanaka, H | 1 |
| Muguruma, K | 1 |
| Sakurai, K | 1 |
| Kubo, N | 1 |
| Nagahara, H | 1 |
| Kimura, K | 1 |
| Amano, R | 1 |
| Noda, E | 1 |
| Maeda, K | 1 |
| Sawada, T | 1 |
| Ohira, M | 1 |
| Ishikawa, T | 1 |
| Hirakawa, K | 1 |
| Glimelius, B | 1 |
| Usuki, H | 1 |
| Ishimura, K | 1 |
| Yachida, S | 1 |
| Hagiike, M | 1 |
| Okano, K | 1 |
| Izuishi, K | 1 |
| Karasawa, Y | 1 |
| Goda, F | 1 |
| Maeta, H | 1 |
| Noie, T | 1 |
| Konishi, T | 1 |
| Nara, S | 1 |
| Ito, K | 1 |
| Harihara, Y | 1 |
| Furushima, K | 1 |
| Petrioli, R | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Marsili, S | 1 |
| Pozzessere, D | 1 |
| Messinese, S | 1 |
| Correale, P | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Tani, F | 1 |
| De Martino, A | 1 |
| Marzocca, G | 1 |
| Lorenzi, M | 1 |
| Giorgi, G | 1 |
| Francini, G | 1 |
| Sakon, M | 1 |
| Nagano, H | 1 |
| Monden, M | 1 |
| Wang, HM | 1 |
| Kopp, HG | 1 |
| Moerike, K | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Takezako, Y | 1 |
| Ishiguro, Y | 1 |
| Matsubara, J | 2 |
| Ishii, H | 1 |
| Nagase, M | 1 |
| Nakachi, K | 1 |
| Bhandari, MS | 1 |
| Pienta, KJ | 1 |
| Fardig, J | 1 |
| Olson, K | 1 |
| Smith, DC | 1 |
| Inokuchi, M | 1 |
| Kojima, K | 1 |
| Ichikawa, W | 1 |
| Nihei, Z | 1 |
| Kawano, T | 1 |
| Yoshida, K | 1 |
| Ninomiya, M | 1 |
| Takakura, N | 1 |
| Hirabayashi, N | 1 |
| Takiyama, W | 1 |
| Todo, S | 1 |
| Terashima, M | 1 |
| Nishiyama, M | 1 |
| Chao, Y | 1 |
| Li, CP | 1 |
| Chao, TY | 1 |
| Su, WC | 1 |
| Hsieh, RK | 1 |
| Wu, MF | 1 |
| Yeh, KH | 1 |
| Kao, WY | 1 |
| Takahashi, T | 1 |
| Kobayashi, M | 1 |
| Ohno, T | 1 |
| Kamiyama, Y | 1 |
| Aihara, R | 1 |
| Haga, N | 1 |
| Ojima, H | 1 |
| Ohsawa, H | 1 |
| Nakabayashi, T | 1 |
| Takeuchi, K | 1 |
| Kuwano, H | 1 |
| Sheikh, HY | 1 |
| Valle, JW | 1 |
| Palmer, K | 1 |
| Sjursen, A | 1 |
| Craven, O | 1 |
| Wilson, G | 1 |
| Swindell, R | 1 |
| Saunders, MP | 1 |
| Shin, SJ | 1 |
| Ahn, JB | 1 |
| Noh, SH | 1 |
| Roh, JK | 1 |
| Hosokawa, A | 1 |
| Sugiyama, T | 1 |
| Ohtsu, A | 1 |
| Doi, T | 1 |
| Hattori, S | 1 |
| Yano, T | 1 |
| Minashi, K | 1 |
| Muto, M | 1 |
| Yoshida, S | 1 |
| Vormittag, L | 1 |
| Kornek, GV | 1 |
| Gruhsmann, B | 1 |
| Lenauer, A | 1 |
| Föger, A | 1 |
| Depisch, D | 1 |
| Lang, F | 1 |
| Scheithauer, W | 1 |
| Kim, YJ | 1 |
| Im, SA | 1 |
| Lee, KW | 1 |
| Choi, IS | 1 |
| Oh, DY | 1 |
| Lee, SH | 1 |
| Kim, JH | 1 |
| Kim, DW | 1 |
| Kim, TY | 1 |
| Kim, SW | 1 |
| Heo, DS | 1 |
| Yoon, YB | 1 |
| Bang, YJ | 1 |
| Scalamogna, R | 1 |
| Brugnatelli, S | 1 |
| Tinelli, C | 1 |
| Sagrada, P | 1 |
| Gattoni, E | 1 |
| Tronconi, MC | 1 |
| Riccardi, A | 1 |
| Luchena, G | 1 |
| Corazza, GR | 1 |
| Sawada, Y | 1 |
| Shimoda, M | 1 |
| Shimoda, S | 1 |
| Nagahama, T | 1 |
| Nishioka, K | 1 |
| Aoki, T | 1 |
| Hatano, H | 1 |
| Komori, T | 1 |
| Matsumoto, T | 1 |
| Uemura, Y | 1 |
| Moriwaki, T | 1 |
| Shimoda, T | 1 |
| Kajiwara, T | 1 |
| Nakajima, TE | 1 |
| Okayama, Y | 1 |
| Oka, T | 1 |
| Shien, T | 1 |
| Shimizu, C | 1 |
| Akashi-Tanaka, S | 1 |
| Yonemori, K | 1 |
| Kohno, T | 1 |
| Hojo, T | 1 |
| Ando, M | 1 |
| Katsumata, N | 1 |
| Fujiwara, Y | 1 |
| Nakajo, A | 1 |
| Hokita, S | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Etoh, T | 1 |
| Hamanoue, M | 1 |
| Maenohara, S | 1 |
| Iwashita, T | 1 |
| Komatsu, H | 1 |
| Satoh, K | 1 |
| Aridome, K | 1 |
| Natsugoe, S | 1 |
| Takiuchi, H | 1 |
| Maehara, Y | 1 |
| Aikou, T | 1 |
| Kim, YH | 1 |
| Cheong, SK | 1 |
| Lee, JD | 1 |
| Park, JS | 1 |
| Shin, SW | 1 |
| Manziuk, LV | 1 |
| Perevodchikova, NI | 1 |
| Gorbunova, VA | 1 |
| Luk'ianchenko, AB | 1 |
| Abramova, NA | 1 |
| Martin, M | 1 |
| Casado, A | 1 |
| López-Martin, JA | 1 |
| Rodriguez-Lescure, A | 1 |
| Nieto, Y | 1 |
| Ayala, F | 1 |
| Diaz-Rubio, E | 1 |
| Kurebayashi, J | 1 |
| Nukatsuka, M | 1 |
| Fujioka, A | 1 |
| Saito, H | 1 |
| Takeda, S | 1 |
| Unemi, N | 1 |
| Fukumori, H | 1 |
| Kurosumi, M | 1 |
| Sonoo, H | 1 |
| Dickson, RB | 1 |
| Ono, Y | 1 |
| Ohshima, S | 1 |
| Kuriyama, M | 1 |
| Kawada, Y | 1 |
| Shimizu, H | 1 |
| Price, T | 1 |
| Hill, M | 1 |
| Shinohara, H | 1 |
| Niki, M | 1 |
| Nomura, E | 1 |
| Nishiguchi, K | 1 |
| Okuzawa, M | 1 |
| Chon, Y | 1 |
| Tanigawa, N | 1 |
| Alonso, V | 1 |
| Escudero, P | 1 |
| Zorrilla, M | 1 |
| Isla, MD | 1 |
| Herrero, A | 1 |
| Mayordomo, JI | 1 |
| Martinez-Trufero, J | 1 |
| Sáenz, A | 1 |
| Tres, A | 1 |
| Antón, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02836977] | 400 participants (Anticipated) | Interventional | 2016-03-31 | Active, not recruiting | |||
| Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer[NCT00392899] | Phase 3 | 2,025 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Prospective Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy[NCT00952926] | 55 participants (Actual) | Observational | 2009-10-31 | Completed | |||
| DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer[NCT04927897] | 50 participants (Anticipated) | Observational | 2022-08-16 | Recruiting | |||
| Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial[NCT05338866] | 58 participants (Anticipated) | Observational | 2022-01-01 | Enrolling by invitation | |||
| A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer[NCT01110941] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)[NCT00498225] | Phase 3 | 834 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer[NCT02090153] | Phase 2 | 39 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial[NCT02704143] | 63 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| A Phase II Study of Docetaxel, Oxaliplatin and S-1 (DOS) in Patients With Advanced Gastric Cancer[NCT00525005] | Phase 2 | 44 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer[NCT00154778] | Phase 2 | 55 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 6.5 |
| 5-FU/Cisplatin | 5.8 |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 8.6 |
| 5-FU/Cisplatin | 7.9 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).
| Intervention | Percentage of patients in each group (Number) |
|---|---|
| S-1/Cisplatin | 29.1 |
| 5-FU/Cisplatin | 31.9 |
The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 4.8 |
| 5-FU/Cisplatin | 5.5 |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 3.8 |
| 5-FU/Cisplatin | 3.8 |
Median overall survival is calculated by Kaplan-Meier method. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 14.4 |
The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: Within 90 days after completion of SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 9 |
The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: 90 days after SBRT
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 5 |
One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled. (NCT02704143)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Combination of Cyberknife With S-1 | 46 |
Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704143)
Timeframe: 3 years
| Intervention | months (Median) |
|---|---|
| Combination of Cyberknife With S-1 | 10.1 |
The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively). (NCT02704143)
Timeframe: 1 years
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global health status | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | Fatigue | Nausea and vomiting | Pain | Dyspnea | Insomnia | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| Combination of Cyberknife With S-1 | 50.0 | 64.2 | 54.8 | 68.5 | 73.8 | 74.6 | 46.7 | 55.3 | 48.7 | 9.5 | 19.0 | 59.2 | 13.2 | 13.7 | 31.2 |
7 reviews available for tegafur and Disease Exacerbation
| Article | Year |
|---|---|
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxy | 2013 |
S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression | 2014 |
S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribu | 2014 |
The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progress | 2014 |
[A case report of a stage IV gastric cancer patient with rapid progression of liver metastases induced by postoperative anastomotic leakage].
Topics: Adult; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2012 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inh | 2003 |
[Recent progress in chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2004 |
64 trials available for tegafur and Disease Exacerbation
| Article | Year |
|---|---|
Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2018 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2019 |
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycy | 2013 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2013 |
S-1 plus CIK as second-line treatment for advanced pancreatic cancer.
Topics: Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Disease Progression; Drug Combinations; F | 2013 |
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; | 2014 |
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2015 |
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; De | 2014 |
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease | 2016 |
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2016 |
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2016 |
[Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Capsules; Dihyd | 2016 |
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2016 |
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease | 2017 |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2017 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2008 |
A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2009 |
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Drug Combinations; F | 2009 |
Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Disease Progression; | 2008 |
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2009 |
A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; D | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colore | 2010 |
Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cytokines; Disease Progression; | 2010 |
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2011 |
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Co | 2011 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Ne | 2010 |
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Cu | 2010 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; | 2011 |
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Interval | 2010 |
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract | 2012 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2011 |
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2011 |
Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Surviv | 2011 |
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Com | 2012 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2012 |
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Dise | 2013 |
Development of clinical pathway in S-1 chemotherapy for gastric cancer.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Critical Pathways; Disease Progressio | 2003 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2005 |
An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Male; | 2005 |
An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Male; | 2005 |
An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Male; | 2005 |
An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Male; | 2005 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxyc | 2005 |
Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2006 |
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dis | 2006 |
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2006 |
An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2006 |
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; | 2006 |
Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2007 |
A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Disease Progression | 2007 |
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2008 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2008 |
Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineop | 1996 |
[Biochemical modulation by leucovorin of the antineoplastic effect of fluorofur in disseminated colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Drug Admini | 1996 |
Endocrine plus uracil/tegafur therapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 1999 |
UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplas | 2000 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coh | 2001 |
63 other studies available for tegafur and Disease Exacerbation
| Article | Year |
|---|---|
Rapidly progressive glomerulonephritis caused by tegafur/gimeracil/oteracil resulted in diabetes nephropathy, in a patient with minor risk of diabetes nephropathy: a case report.
Topics: Aged; Asian People; Biopsy; Colorectal Neoplasms; Creatinine; Diabetic Nephropathies; Disease Progre | 2020 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Prog | 2020 |
Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dis | 2021 |
Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2017 |
[Chemoradiotherapy with S-1 for Recurrence Cases of Colorectal Cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Colorectal Neoplasms; Disease Progression; Drug | 2018 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cap | 2018 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; D | 2018 |
No role for induction chemotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2018 |
[Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclobutanes; Disease Progression; Disease-Free Surv | 2018 |
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Disease Progr | 2013 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2013 |
Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2013 |
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; | 2013 |
Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Antineo | 2014 |
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Fem | 2014 |
S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Deoxycytidine; Disea | 2014 |
Extrapulmonary small cell carcinoma in head and neck.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Sm | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy; Brachytherapy; | 2015 |
Number of Lymph Nodes in Rectal Cancer is Correlated with Response to Preoperative Chemoradiotherapy but is not Associated with Patient Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; D | 2014 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 2016 |
Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer.
Topics: Antimetabolites, Antineoplastic; Disease Progression; Drug Combinations; Female; Humans; Middle Aged | 2014 |
[An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell | 2015 |
Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease | 2015 |
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Disease Pro | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C | 2016 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cispla | 2017 |
[Curative Resection for Chemorefractory Advanced Gastric Cancer with Pancreatic Invasion by Pancreatoduodenectomy - A Case Report].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2016 |
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2008 |
Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Combination | 2008 |
[A successful case of advanced nasal adenocarcinoma treated with tumor dormancy therapy with S -1 alone].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dis | 2008 |
Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
[A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
[S-1 activity in non-small cell lung cancer in clinical practice].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2009 |
S-1 monotherapy in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neopl | 2009 |
[The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dise | 2009 |
[Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2009 |
A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2010 |
Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2010 |
A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplat | 2010 |
S-1 is an active anticancer agent for advanced thymic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Disease-Free Survival; Drug C | 2010 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2011 |
Second-line docetaxel plus cisplatin for advanced gastric cancer showing resistance to S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
[Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Drug Combinations; Female; Humans; M | 2011 |
Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2012 |
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; C | 2012 |
A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cisplatin; Disease Progression; Drug Combinat | 2012 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administra | 2005 |
Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progress | 2006 |
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Combi | 2007 |
UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2007 |
UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2007 |
[Progression of gastric cancer observed for three and a half years under S-1 administration].
Topics: Disease Progression; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Male; Middle Aged; Oxonic | 2007 |
[Two patients of progressive gastric cancer accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC successfully controlled by combination of S-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease Progression; Drug | 2007 |
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2008 |
Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2008 |
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea | 1997 |
Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; | 1997 |
[A case of stage IV gastric cancer with multiple liver metastases and carcinomatous ascites responding to TS-1 for six months before progression].
Topics: Aged; Antimetabolites, Antineoplastic; Ascitic Fluid; Disease Progression; Drug Combinations; Humans | 2001 |